GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

GETI.B

210.7

-1.08%↓

CAMX

597.5

+2.4%↑

BIOAB

317.4

+3.52%↑

VITR

130

-1.59%↓

AMBEA

141.9

+2.09%↑

Search

Elekta AB

Abrir

56.3 0.54

Visão Geral

Variação de preço das ações

24h

Atual

Mín

55.65

Máximo

56.55

Indicadores-chave

By Trading Economics

Rendimento

94M

230M

Vendas

424M

4.1B

P/E

Médio do Setor

74.079

76.798

EPS

0.64

Rendimento de Dividendos

4.32

Margem de lucro

5.651

Funcionários

4,484

EBITDA

20M

529M

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.32%

2.37%

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

4.9B

22B

Abertura anterior

55.76

Fecho anterior

56.3

Elekta AB Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

18 de dez. de 2025, 23:54 UTC

Ações em Alta

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 de dez. de 2025, 23:51 UTC

Ganhos

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 de dez. de 2025, 23:39 UTC

Grandes Movimentos do Mercado

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 de dez. de 2025, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 de dez. de 2025, 21:40 UTC

Ganhos

Nike Sales Tick Up, But China Weakness Persists

18 de dez. de 2025, 23:45 UTC

Conversa de Mercado

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 de dez. de 2025, 23:37 UTC

Conversa de Mercado
Ganhos

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 de dez. de 2025, 23:36 UTC

Conversa de Mercado

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 de dez. de 2025, 23:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 de dez. de 2025, 23:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 de dez. de 2025, 23:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 de dez. de 2025, 22:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 de dez. de 2025, 22:58 UTC

Aquisições, Fusões, Aquisições de Empresas

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 de dez. de 2025, 22:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 de dez. de 2025, 22:56 UTC

Aquisições, Fusões, Aquisições de Empresas

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 de dez. de 2025, 22:55 UTC

Ganhos

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 de dez. de 2025, 21:59 UTC

Ganhos

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 de dez. de 2025, 21:50 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

18 de dez. de 2025, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

18 de dez. de 2025, 21:35 UTC

Ganhos

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 de dez. de 2025, 21:31 UTC

Ganhos

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Greater China Rev Down 17% >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q EPS 53c >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Apparel Rev $3.91B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Equipment Rev $550M >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q N Amer Rev $5.63B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Footwear Rev $7.66B >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 de dez. de 2025, 21:15 UTC

Ganhos

Nike 2Q Greater China Rev $1.42B >NKE

Comparação entre Pares

Variação de preço

Elekta AB Previsão

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Elekta AB

Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
help-icon Live chat